Stage Iva Uterine Corpus Cancer Ajcc v8 Clinical Trials
4 recruiting trials for Stage Iva Uterine Corpus Cancer Ajcc v8. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Stage Iva Uterine Corpus Cancer Ajcc v8 clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 75% (3 studies); the largest phase groups are Phase 1: 3, Phase 1 / Phase 2: 1.
Research is led by M.D. Anderson Cancer Center (2), City of Hope Medical Center (1), Mayo Clinic (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Biopsy (procedure, 2 trials), followed by Cisplatin, Doxorubicin.
Track Stage Iva Uterine Corpus Cancer Ajcc v8 trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or...
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric),...
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have...
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor...
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel...
This phase Ib trial tests the safety, side effects, and best dose of tumor treating fields therapy in combination with either cabozantinib or nab-paclitaxel and atezolizumab in...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Stage Iva Uterine Corpus Cancer Ajcc v8, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Stage Iva Uterine Corpus Cancer Ajcc v8, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Stage Iva Uterine Corpus Cancer Ajcc v8, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.